Information Provided By:
Fly News Breaks for January 16, 2020
Jan 16, 2020 | 07:07 EDT
H.C. Wainwright analyst Joseph Pantginis says Rigel Pharmaceuticals' launch of Tavalisse remains encouraging after the company preannounced Tavalisse Q4 revenue of $13.8M, above his estimate of $12.5M. The analyst keeps a BUy rating on the shares with an $8 price target.
News For RIGL From the Last 2 Days
There are no results for your query RIGL